Travere Therapeutics (TVTX) return on equity (ROE)
Travere Therapeutics (TVTX) earned a return on equity of -22.2% in fiscal 2025 (the year ended December 31, 2025). That is 522.0 percentage points higher than the -544.3% of fiscal 2024. Figures as of 18 Nov 2026, 00:30 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Return on equity, fiscal 2025
- -22.2%
- Change on fiscal 2024
- +522.0 pts
- Highest on record
- 39.1%fiscal 2015
- Lowest on record
- -649.9%fiscal 2022
- Fiscal years on record
- 112015–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Travere Therapeutics return on equity (ROE), in more detail
Across the 11 fiscal years on record (2015–2025), the highest was 39.1% in fiscal 2015 and the lowest -649.9% in fiscal 2022. The fiscal 2025 figure is higher than in 70% of the 10 earlier fiscal years on record, whose median is -57.5%.
Return on equity by fiscal year
Travere Therapeutics return on equity (ROE), year by year
| Fiscal year | Return on equity | Change | Year ended |
|---|---|---|---|
| 2025 | -22.2% | 522.0 pts up | |
| 2024 | -544.3% | 488.8 pts down | |
| 2023 | -55.5% | 594.4 pts up | |
| 2022 | -649.9% | 590.3 pts down | |
| 2021 | -59.6% | 20.6 pts up | |
| 2020 | -80.2% | 14.0 pts down | |
| 2019 | -66.2% | 33.9 pts down | |
| 2018 | -32.3% | 11.9 pts down | |
| 2017 | -20.4% | 4.8 pts down | |
| 2016 | -15.6% | 54.6 pts down | |
| 2015 | 39.1% | — |
Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.
How to read it
It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.
Return on equity at health care companies of similar size
| Company | Return on equity | Fiscal year |
|---|---|---|
| MiniMed Group MMED | -9.2% | 2026 |
| Adaptive Biotechnologies ADPT | -27.2% | 2025 |
| Heartflow HTFL | -38.8% | 2025 |
| CRISPR Therapeutics CRSP | -30.3% | 2025 |
| Travere Therapeutics TVTX | -22.2% | 2025 |
| Option Care Health OPCH | 15.7% | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Travere Therapeutics, figure by figure
- Travere Therapeutics market cap
- Travere Therapeutics revenue
- Travere Therapeutics earnings
- Travere Therapeutics earnings per share (EPS)
- Travere Therapeutics P/E ratio
- Travere Therapeutics P/S ratio
- Travere Therapeutics P/B ratio
- Travere Therapeutics free cash flow
- Travere Therapeutics operating margin
- Travere Therapeutics dividend
- Travere Therapeutics shares outstanding
- Travere Therapeutics total debt
- Travere Therapeutics cash on hand
- Travere Therapeutics total assets
- Travere Therapeutics return on invested capital (ROIC)
Travere Therapeutics (TVTX) overview: price, valuation and scorecardAll health care companies by market value
Travere Therapeutics return on equity (ROE): questions and answers
What is Travere Therapeutics's return on equity?
Travere Therapeutics (TVTX) earned a return on equity of -22.2% in fiscal 2025 (the year ended December 31, 2025). That is 522.0 percentage points higher than the -544.3% of fiscal 2024.
Is Travere Therapeutics's return on equity high or low compared with its own history?
The fiscal 2025 figure is higher than in 70% of the 10 earlier fiscal years on record, whose median is -57.5%.
What are the highest and lowest return on equity figures on record for Travere Therapeutics?
Across the 11 fiscal years on record (2015–2025), the highest was 39.1% in fiscal 2015 and the lowest -649.9% in fiscal 2022.
How is Travere Therapeutics's return on equity calculated?
Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.
Fiscal years are named for the calendar year they end in.
Learn: return on equity (ROE)
All stocks guides →- Return on invested capital (ROIC) vs ROE and ROA
Return on invested capital (ROIC) is after-tax operating profit divided by the money tied up in the business: debt plus equity, less cash. A company earning $15 million after tax on $100 million of invested capital has a 15% ROIC. Unlike return on equity, it does not rise just because a company borrows more.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Travere Therapeutics (TVTX) return on equity (ROE)”, data as of 18 November 2026. https://funkfolio.com/stock/TVTX/roe
Underlying data: the company's filings with the SEC and Yahoo Finance.